Alzamend Neuro's Total Assets for the quarter that ended in Jan. 2025 was $4.18 Mil.
During the past 12 months, Alzamend Neuro's average Total Assets Growth Rate was 63.60% per year.
During the past 3 years, the average Total Assets Growth Rate was -36.20% per year.
During the past 5 years, the average Total Assets Growth Rate was -28.80% per year.
During the past 6 years, Alzamend Neuro's highest 3-Year average Total Assets Growth Rate was -23.40%. The lowest was -36.20%. And the median was -32.30%.
The historical data trend for Alzamend Neuro's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Alzamend Neuro's Total Assets for the fiscal year that ended in Apr. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro (NAS:ALZN) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Jan. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Alzamend Neuro's Asset Turnover for the quarter that ended in Jan. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Alzamend Neuro Total Assets Related Terms
Thank you for viewing the detailed overview of Alzamend Neuro's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALZN has been successfully added to your 